Company Description

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain.

Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.

The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital.

The company was founded in 2015 and is based in Wilmington, Delaware.

NRx Pharmaceuticals, Inc.

Country	United States
Founded	2015
Industry	Biotechnology
Sector	Healthcare
CEO	Jonathan Javitt

Contact Details

Address: 1201 Orange Street, Suite 600 Wilmington, Delaware 19801 United States
Phone	484 254 6134
Website	nrxpharma.com

Stock Details

Ticker Symbol	NRXPW
Exchange	NASDAQ
Stock Type	Warrants
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001719406
CUSIP Number	629444118
ISIN Number	US6294441182

Key Executives

Name	Position
Matthew Patrick Duffy	Chief Business Officer and Co-Chief Executive Officer of Hope Therapeutics
Dr. Jonathan C. Javitt M.D., M.P.H.	Co-Founder, Chief Scientist Officer, Chairman and Interim Chief Executive Officer
Richard Clavano Narido	Chief Financial Officer and Treasurer
Dr. Riccardo Panicucci Ph.D.	Chief Manufacturing and Technology Officer
Suzanne Messere	Investor Relations
Dr. Philip T. Lavin Ph.D.	Chief Methodologist